Oksana A. Makeeva

Oksana A. Makeeva

Auto-generated profile, based on publicly available information

Oksana A. Makeeva

Neuropsychology Testing Center, Nebbiolo LLC Tomsk Russia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2008 in Pharmacogenomics
Verified
Journal Article
Closed access
OMOksana Makeeva
Oksana Makeeva
VSVadim A. Stepanov
Vadim A. Stepanov
VPValery Puzyrev
Valery Puzyrev
DGDavid B Goldstein
David B Goldstein
IGIris Grossman
Iris Grossman
To study the frequency distribution of cytochrome P450 (CYP) functional genetic variants in five Eurasian populations from the territory of Siberia in Russia. Unrelated healthy Tuvinians, Buryats, Altaians, Yakuts and Russians (n = 87-88) were genotyped for CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*3, CYP3A5*3 and CYP3A5*6. Standard pairwise genetic distances, locus-specific and global Fst statistics were calculated. CYP allele and genotype frequencies demonstrated significant variability. Overall, the degree of between-population variance displayed by CYP SNPs was lower than that recorded from neutral short tandem repeats and Alu-insertion polymorphism, indicating evolutionary conservation of CYP polymorphisms. CYP-based genetic distances were well correlated with the geographic distances across populations (r = 0.822, p = 0.008). Although the tested variants were present in the neighboring, yet secluded, populations at the expected range of frequencies, the observed frequencies were significantly variable across Eurasian populations, indicating potential relevance to clinical decision making.

26 April 2010 in Personalized Medicine
Verified
Journal Article
Closed access
OMOksana A Makeeva
Oksana A Makeeva
VMValentina V Markova
Valentina V Markova
ARAllen D Roses
Allen D Roses
VPValery P Puzyrev
Valery P Puzyrev
Many new genetic tests for common multifactorial disorders are becoming available to individuals, including direct-to-consumer genotyping services. Typically, studies of public attitudes reveal a high level of interest for individual genotyping. In a Russian urban population, 85% of 2000 respondents answered positively to a question about their own willingness to undergo predictive genetic testing for preventable health conditions. Gender, age and health status significantly influenced response. Multivariate discriminant analyses revealed that wanting to know about probable future diseases, readiness to improve lifestyles and an interest in learning about individual genome characteristics are the most important predictors for wanting to be tested. Along with the high level of interest, highly overestimated expectations were encountered in many studies. With the low predictive abilities of currently available genetic tests for common disorders, proper interpretation of the data and genetic counseling are e...

22 July 2014 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
Kathleen HaydenKathleen Hayden
Kathleen Hayden
OMOksana A. Makeeva
Oksana A. Makeeva
LNL. Kristin Newby
L. Kristin Newby
BPBrenda L. Plassman
Brenda L. Plassman
VMValentina V. Markova
Valentina V. Markova
TITOMSK‐DUKE Study Group Investigators
TOMSK‐DUKE Study Group Investigators

15 September 2015 in Acta Naturae
Verified
Journal Article
Open access
PDF file
OMO. A. Makeeva
O. A. Makeeva
ASA. A. Sleptsov
A. A. Sleptsov
EKE. V. Kulish
E. V. Kulish
OBO. L. Barbarash
O. L. Barbarash
AMA. M. Mazur
A. M. Mazur
VPV. P. Puzyrev
V. P. Puzyrev
Comorbidity or a combination of several diseases in the same individual is a common and widely investigated phenomenon. However, the genetic background for non-random disease combinations is not fully understood. Modern technologies and approaches to genomic data analysis enable the investigation of the genetic profile of patients burdened with several diseases (polypathia, disease conglomerates) and its comparison with the profiles of patients with single diseases. An association study featuring three groups of patients with various combinations of cardiovascular disorders and a control group of relatively healthy individuals was conducted. Patients were selected as follows: presence of only one disease, ischemic heart disease (IHD); a combination of two diseases, IHD and arterial hypertension (AH); and a combination of several diseases, including IHD, AH, type 2 diabetes mellitus (T2DM), and hypercholesterolemia (HC). Genotyping was performed using the My Gene genomic service (www.i-gene.ru). An analysis of 1,400 polymorphic genetic variants and their associations with the studied phenotypes are presented. A total of 14 polymorphic variants were associated with the phenotype IHD only, including those in the APOB, CD226, NKX2-5, TLR2, DPP6, KLRB1, VDR, SCARB1, NEDD4L, and SREBF2 genes, and intragenic variants rs12487066, rs7807268, rs10896449, and rs944289. A total of 13 genetic markers were associated with the IHD and AH phenotype, including variants in the BTNL2, EGFR, CNTNAP2, SCARB1, and HNF1A genes, and intragenic polymorphisms rs801114, rs10499194, rs13207033, rs2398162, rs6501455, and rs1160312. A total of 14 genetic variants were associated with a combination of several diseases of cardiovascular continuum (CVC), including those in the TAS2R38, SEZ6L, APOA2, KLF7, CETP, ITGA4, RAD54B, LDLR, and MTAP genes, along with intragenic variants rs1333048, rs1333049, and rs6501455. One common genetic marker was identified for the IHD only and IHD and AH phenotypes: rs4765623 in the SCARB1 gene; two common genetic markers, rs663048 in SEZ6L and intragenic rs6501455, were identified for the IHD and AH phenotype and a combination of several diseases (syntropy); there were no common genetic markers for the syntropy and IHD only phenotypes. Classificatory analysis of the relationships between the associated genes and metabolic pathways revealed that lipid-metabolizing genes are involved in the development of all three CVC variants, whereas immunity-response genes are specific to the IHD only phenotype. The study demonstrated that comorbidity presents additional challenges in association studies of disease predisposition, since the genetic profile of combined forms of pathology can be markedly different from those for isolated single forms of a disease.

19 May 2009 in Personalized Medicine
Verified
Journal Article
Closed access
OMOksana A Makeeva
Oksana A Makeeva
VMValentina V Markova
Valentina V Markova
VPValery P Puzyrev
Valery P Puzyrev
In contrast to the modest progress made in the interpretation and clinical application of genomic data, genotyping technologies have experienced great progress. Genotyping costs are progressively decreasing making individual genotyping more commonly available. Financial availability of individual genome analysis and the strong desire of many people to know about their individual genomic characteristics, promotes the marketing of genetic tests of variable predictive value directly to the public. A survey of 2000 Russian respondents revealed very positive attitudes and beliefs towards these genetic developments: 85% of surveyed individuals would like to have their genetic risk for avoidable diseases estimated, and 89% responded stating that they would try to change their lifestyle by giving up bad habits, following a recommended diet or taking medications if a high risk of disease was identified. It is believed that with time, validated genetic information will find its rightful place in medicine, by supplementing phenotypic clinical data with validated genetic interpretations.

5 July 2010 in Personalized Medicine
Verified
Journal Article
Closed access
VPValery P Puzyrev
Valery P Puzyrev
OMOksana A Makeeva
Oksana A Makeeva
MFMaxim Freidin
Maxim Freidin
The concept of syntropic diseases was proposed at the beginning of the last century to emphasize the phenomenon of nonrandom co-occurrence of human disorders. Common genes underlying specific syntropic diseases were called syntropic genes. The application of this concept to contemporary genomic studies will facilitate the understanding of the molecular basis of complex diseases, provide future direction for discovering new targets for therapy and prognosis, and may even lead to the reassessment of disease classification for the practice of more precise personalized medicine. With the acceptance of the syntropic genes theory, new genetic tests, focused on markers pointing to a set of pathogenetically linked diseases rather than to a single nosology, can be developed.